US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
US4741900A
(en)
|
1982-11-16 |
1988-05-03 |
Cytogen Corporation |
Antibody-metal ion complexes
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
GB8430252D0
(en)
|
1984-11-30 |
1985-01-09 |
Beecham Group Plc |
Compounds
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
ES2054667T3
(en)
|
1986-04-28 |
1994-08-16 |
Cetus Oncology Corp |
MONOCLONAL ANTIBODIES AGAINST C5A AND DES-ARG74-C5A, THEIR PRODUCTION AND USE.
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
US5256642A
(en)
|
1988-04-01 |
1993-10-26 |
The Johns Hopkins University |
Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
|
NZ230747A
(en)
|
1988-09-30 |
1992-05-26 |
Bror Morein |
Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5166322A
(en)
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
US5244800A
(en)
|
1990-04-27 |
1993-09-14 |
The Uab Research Foundation |
Crystals of human complement factor d that are triclinic
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
LU91067I2
(en)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab and its variants and immunochemical derivatives including immotoxins
|
WO1993000109A1
(en)
|
1991-06-28 |
1993-01-07 |
Genentech, Inc. |
Method of stimulating immune response using growth hormone
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
DE69333807T2
(en)
|
1992-02-06 |
2006-02-02 |
Chiron Corp., Emeryville |
MARKERS FOR CANCER AND BIOSYNTHETIC BINDEPROTEIN THEREFOR
|
US5456909A
(en)
|
1992-08-07 |
1995-10-10 |
T Cell Sciences, Inc. |
Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
|
ATE161192T1
(en)
|
1992-08-21 |
1998-01-15 |
Genentech Inc |
METHOD FOR TREATING A DISORDER MEDIATED BY LFA-1
|
WO1994012219A2
(en)
|
1992-11-25 |
1994-06-09 |
Amgen Boulder Inc. |
Modified insulin-like growth factors
|
US5861156A
(en)
|
1993-01-08 |
1999-01-19 |
Creative Biomolecules |
Methods of delivering agents to target cells
|
WO1994022466A1
(en)
|
1993-04-07 |
1994-10-13 |
Synergen, Inc. |
Methods of using insulin-like growth factor binding proteins
|
US5856300A
(en)
|
1994-05-12 |
1999-01-05 |
T Cell Sciences, Inc. |
Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
|
US5679546A
(en)
|
1993-09-24 |
1997-10-21 |
Cytomed, Inc. |
Chimeric proteins which block complement activation
|
US5627264A
(en)
|
1994-03-03 |
1997-05-06 |
Alexion Pharmaceuticals, Inc. |
Chimeric complement inhibitor proteins
|
DE69533921T2
(en)
|
1994-03-23 |
2005-12-01 |
Alexion Pharmaceuticals, Inc., New Haven |
METHOD FOR REDUCING MALFUNCTIONS OF IMMUNE SYSTEM AND HEMOSTASE DURING EXTRACORPOREAL CIRCULATION
|
US5534615A
(en)
|
1994-04-25 |
1996-07-09 |
Genentech, Inc. |
Cardiac hypertrophy factor and uses therefor
|
US5919623A
(en)
|
1994-04-27 |
1999-07-06 |
St. James's And Seacroft University Hospitals Nhs Trust |
Nucleic acid mutation assays
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
US5679345A
(en)
|
1994-06-02 |
1997-10-21 |
The Johns Hopkins University |
Method for preventing complement-dependent rejection of organ or tissue transplants
|
WO2001004311A1
(en)
|
1999-07-07 |
2001-01-18 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US5679564A
(en)
|
1994-10-05 |
1997-10-21 |
Antex Biologics, Inc. |
Methods for producing enhanced antigenic campylobacter bacteria and vaccines
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
DE69635026T2
(en)
|
1995-09-21 |
2006-05-24 |
Genentech Inc., San Francisco |
VARIANTS OF HUMAN GROWTH HORMONE
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
US20050197285A1
(en)
|
1997-03-07 |
2005-09-08 |
Rosen Craig A. |
Human secreted proteins
|
WO1999040100A1
(en)
|
1998-02-09 |
1999-08-12 |
Human Genome Sciences, Inc. |
45 human secreted proteins
|
US6472520B2
(en)
|
1997-03-21 |
2002-10-29 |
The Trustees Of Columbia University In The City Of New York |
Rat PEG-3 promoter
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
TR199903123T2
(en)
|
1997-04-07 |
2000-05-22 |
Genentech, Inc. |
Anti-Vegf antikorlar�.
|
US5994511A
(en)
*
|
1997-07-02 |
1999-11-30 |
Genentech, Inc. |
Anti-IgE antibodies and methods of improving polypeptides
|
DE69838552T2
(en)
|
1997-07-14 |
2008-05-21 |
Bolder Biotechnology, Inc., Louisville |
DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS
|
US6410708B1
(en)
|
1997-11-21 |
2002-06-25 |
Genentech, Inc. |
Nucleic acids encoding A-33 related antigen polypeptides
|
PT1007092E
(en)
|
1997-08-26 |
2006-12-29 |
Amgen Fremont Inc |
A process for inhibiting complement activation via the alternative pathway
|
US8088386B2
(en)
|
1998-03-20 |
2012-01-03 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
US8007798B2
(en)
|
1997-11-21 |
2011-08-30 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
DE69840105D1
(en)
|
1997-11-21 |
2008-11-20 |
Genentech Inc |
PLATE-SPECIFIC ANTIGENES AND THEIR PHARMACEUTICAL USE
|
US7282565B2
(en)
|
1998-03-20 |
2007-10-16 |
Genentech, Inc. |
PRO362 polypeptides
|
US7419663B2
(en)
|
1998-03-20 |
2008-09-02 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
US7005504B2
(en)
|
1998-01-22 |
2006-02-28 |
Genentech, Inc. |
Antibody fragment-peg conjugates
|
PT1054693E
(en)
|
1998-02-20 |
2009-01-22 |
Genentech Inc |
Inhibitors of complement activation
|
US6956107B2
(en)
|
1998-02-20 |
2005-10-18 |
Tanox, Inc. |
Inhibitors of complement activation
|
US7112327B2
(en)
|
1998-02-20 |
2006-09-26 |
Tanox, Inc. |
Inhibition of complement activation
|
EP1490386B1
(en)
|
1998-03-10 |
2008-08-13 |
Genentech, Inc. |
Novel polypeptide and nucleic acids encoding the same
|
AU5587799A
(en)
|
1998-08-27 |
2000-03-21 |
Incyte Pharmaceuticals, Inc. |
Protein transport-associated molecules
|
US6376653B1
(en)
|
1998-09-28 |
2002-04-23 |
Smithkline Beecham Plc |
Tie2 antagonist antibodies
|
KR100468978B1
(en)
|
1998-12-16 |
2005-02-02 |
제넨테크, 인크. |
Secreted and Transmembrane Polypeptides and Nucleic Acids Encoding the Same
|
ES2327785T3
(en)
|
1998-12-22 |
2009-11-03 |
Genentech, Inc. |
PROCEDURES AND COMPOUNDS TO INHIBIT THE GROWTH OF NEOPLASTIC CELLS.
|
WO2000042072A2
(en)
|
1999-01-15 |
2000-07-20 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
CA2362427A1
(en)
|
1999-03-08 |
2000-09-14 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
DE60045681D1
(en)
|
1999-03-11 |
2011-04-14 |
Merck Serono Sa |
VASCULAR ADHESION MOLECULES AND MODULATION OF THEIR FUNCTION
|
US6642353B1
(en)
|
1999-03-17 |
2003-11-04 |
Chugai Seiyaku Kabushiki Kaisha |
Peptide ligands for the erythropoietin receptor
|
AU1604401A
(en)
|
1999-11-19 |
2001-05-30 |
Human Genome Sciences, Inc. |
18 human secreted proteins
|
CA2496312A1
(en)
|
1999-12-01 |
2001-06-07 |
Kevin P. Baker |
Colon tumour marker pro4799 polypeptides and nucleic acids encoding the same
|
WO2001058526A2
(en)
|
2000-02-10 |
2001-08-16 |
Alexion Pharmaceuticals, Inc. |
Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof
|
US6821775B1
(en)
|
2000-02-11 |
2004-11-23 |
Genvec, Inc. |
Viral vector encoding pigment epithelium-derived factor
|
PT1265929E
(en)
|
2000-03-23 |
2009-10-15 |
Genentech Inc |
Anti-c2/c2a inhibitors of complement activation
|
DK2026073T3
(en)
|
2000-04-29 |
2016-07-25 |
Univ Iowa Res Found |
Diagnosis and treatment of macular degeneration-related disorders
|
EP1309620A2
(en)
|
2000-06-23 |
2003-05-14 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
CA2416538A1
(en)
|
2000-07-20 |
2002-01-31 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
PT1325033E
(en)
|
2000-10-10 |
2010-04-15 |
Genentech Inc |
Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
|
EP1324776B2
(en)
|
2000-10-12 |
2018-03-21 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
WO2002030986A2
(en)
|
2000-10-13 |
2002-04-18 |
Biogen, Inc. |
HUMANIZED ANTI-LT-β-R ANTIBODIES
|
WO2002072636A2
(en)
|
2000-12-28 |
2002-09-19 |
Altus Biologics Inc. |
Crystals of whole antibodies and fragments thereof and methods for making and using them
|
US20040077575A1
(en)
|
2002-01-11 |
2004-04-22 |
Giordano Giovan Giacomo |
Inhibition of pathological angiogenesis in vivo
|
US6867189B2
(en)
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
BRPI0211953B8
(en)
|
2001-08-17 |
2021-05-25 |
Genentech Inc |
monoclonal antibody or antigen-binding fragment that binds to c5 and c5a without the prevention of c5b formation, cell lineage, pharmaceutical composition, as well as in vitro method to inhibit c5a activity and in vitro diagnostic method
|
EP2348043A1
(en)
|
2001-10-02 |
2011-07-27 |
Genentech, Inc. |
APO-2 ligand variants and uses thereof
|
CA2489348A1
(en)
|
2002-06-24 |
2003-12-31 |
Genentech, Inc. |
Apo-2 ligand/trail variants and uses thereof
|
AU2003294210A1
(en)
|
2002-07-31 |
2004-05-04 |
Seattle Genetics, Inc |
Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
AR040778A1
(en)
|
2002-08-06 |
2005-04-20 |
Glaxo Group Ltd |
ALTERED ANTIBODIES OR FUNCTIONAL FRAGMENTS THAT BIND MAG (GLICOPROTEIN ASSOCIATED WITH HONEY).
|
US20040152105A1
(en)
|
2002-09-06 |
2004-08-05 |
Cytos Biotechnology Ag. |
Immune modulatory compounds and methods
|
US7816497B2
(en)
|
2002-10-30 |
2010-10-19 |
University Of Kentucky |
Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
|
AU2003301813A1
(en)
|
2002-10-30 |
2004-06-07 |
University Of Kentucky Research Foundation |
Methods and animal model for analyzing age-related macular degeneration
|
JP2006518749A
(en)
|
2003-02-21 |
2006-08-17 |
タノックス インコーポレーテッド |
Method for preventing and treating tissue damage associated with ischemia-reperfusion injury
|
RU2232991C1
(en)
|
2003-04-09 |
2004-07-20 |
Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" |
Method for assay of functional activity of human complement factor d
|
KR100512483B1
(en)
|
2003-05-07 |
2005-09-05 |
선바이오(주) |
Novel Preparation method of PEG-maleimide PEG derivatives
|
US7709610B2
(en)
|
2003-05-08 |
2010-05-04 |
Facet Biotech Corporation |
Therapeutic use of anti-CS1 antibodies
|
EP2267028A3
(en)
|
2003-06-30 |
2011-07-27 |
Domantis Limited |
Dual specific single domain antibodies (dAb) conjugated to PEG
|
EP2221317A3
(en)
*
|
2003-06-30 |
2011-07-27 |
Domantis Limited |
PEGylated single domain antibodies (dAb)
|
WO2005014849A2
(en)
|
2003-07-03 |
2005-02-17 |
Euro-Celtique, S.A. |
Genes associated with responses to neuropathic pain
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
US7923010B2
(en)
|
2003-09-11 |
2011-04-12 |
The Board Of Regents Of The University Of Texas System |
Methods and materials for treating autoimmune diseases and conditions
|
US20050169921A1
(en)
|
2004-02-03 |
2005-08-04 |
Leonard Bell |
Method of treating hemolytic disease
|
US20090087854A1
(en)
|
2007-09-27 |
2009-04-02 |
Perlegen Sciences, Inc. |
Methods for genetic analysis
|
US7127355B2
(en)
|
2004-03-05 |
2006-10-24 |
Perlegen Sciences, Inc. |
Methods for genetic analysis
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
NZ580115A
(en)
|
2004-09-23 |
2010-10-29 |
Genentech Inc |
Cysteine engineered antibody light chains and conjugates
|
AU2005314461B2
(en)
|
2004-11-18 |
2012-02-02 |
The Rockefeller University |
Methods and compositions for treating ocular disorders
|
WO2006071856A2
(en)
|
2004-12-23 |
2006-07-06 |
Glycofi, Inc. |
Immunoglobulins comprising predominantly a man5glcnac2 glycoform
|
JP5068175B2
(en)
|
2005-01-04 |
2012-11-07 |
日立化成工業株式会社 |
Primer-generated rolling circle amplification
|
EP2377951A1
(en)
|
2005-02-14 |
2011-10-19 |
University of Iowa Research Foundation |
Methods and reagents for treatment and diagnosis of age-related macular degeneration
|
WO2006133295A2
(en)
|
2005-06-08 |
2006-12-14 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
SUSCEPTIBILITY GENES FOR AGE-RELATED MACULOPATHY (ARM) ON CHROMOSOME 10q26
|
EP2662089A3
(en)
|
2005-10-08 |
2014-02-19 |
Potentia Pharmaceuticals, Inc. |
Compstatin and analogs thereof for eye disorders
|
WO2007056227A2
(en)
|
2005-11-04 |
2007-05-18 |
Genentech, Inc. |
Use of complement pathway inhibitors to treat ocular diseases
|
US20070190057A1
(en)
|
2006-01-23 |
2007-08-16 |
Jian Wu |
Methods for modulating mannose content of recombinant proteins
|
AR059066A1
(en)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
COMBINATIONS OF THE ANGIOPOYETINE INHIBITOR -2 (ANG2) AND THE VASCULAR ENDOTELIAL GROWTH FACTOR INHIBITOR (VEGF)
|
US20080146501A1
(en)
|
2006-02-13 |
2008-06-19 |
University Of Iowa Research Foundation |
Protective complement proteins and age-related macular degeneration
|
BRPI0710110A2
(en)
|
2006-03-31 |
2011-08-02 |
Novartis Ag |
organic compounds
|
CN101478949A
(en)
|
2006-06-16 |
2009-07-08 |
瑞泽恩制药公司 |
VEGF antagonist formulations suitable for intravitreal administration
|
JP2010504361A
(en)
*
|
2006-09-25 |
2010-02-12 |
メディミューン,エルエルシー |
Stable antibody formulations and uses thereof
|
PE20081259A1
(en)
|
2006-11-02 |
2008-10-31 |
Genentech Inc |
HUMANIZED ANTI-FACTOR D ANTIBODIES
|
JP2010526555A
(en)
|
2007-05-11 |
2010-08-05 |
タフツ・メディカル・センター |
Polynucleotides associated with age-related macular degeneration and methods for assessing patient risk
|
AR066660A1
(en)
|
2007-05-23 |
2009-09-02 |
Genentech Inc |
PREVENTION AND TREATMENT OF EYE CONDITIONS ASSOCIATED WITH THEIR COMPLEMENT
|
CN101796072B
(en)
*
|
2007-05-24 |
2014-09-24 |
埃博灵克斯股份有限公司 |
Amino acid sequences directed against RANK-l and polypeptides comprising the same for the treatment of bone diseases and disorders
|
WO2009029587A2
(en)
|
2007-08-24 |
2009-03-05 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating macular degeneration
|
AU2009251499B2
(en)
|
2008-04-18 |
2015-07-16 |
The General Hospital Corporation |
Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk
|
CR20170001A
(en)
*
|
2008-04-28 |
2017-08-10 |
Genentech Inc |
ANTI FACTOR D HUMANIZED ANTIBODIES
|
WO2009134709A2
(en)
|
2008-04-28 |
2009-11-05 |
Tufts Medical Center |
Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
|
CN101724144A
(en)
|
2008-11-03 |
2010-06-09 |
北京键凯科技有限公司 |
Novel multi-arm polyethylene glycol, preparation method and application thereof
|
SI2540843T1
(en)
|
2008-11-05 |
2014-10-30 |
Genentech, Inc. |
Genetic polymorphisms in age-related macular degeneration
|
WO2010075519A2
(en)
|
2008-12-23 |
2010-07-01 |
Massachusetts Eye & Ear Infirmary |
Allelic variants associated with advanced age-related macular degeneration
|
EP2379027A1
(en)
|
2009-01-02 |
2011-10-26 |
Alcon Research, Ltd. |
In-situ refillable ophthalmic implant
|
WO2010085542A2
(en)
|
2009-01-23 |
2010-07-29 |
Novartis Ag |
Biomarkers related to age-related macular degeneration (amd)
|
WO2010088548A1
(en)
|
2009-01-29 |
2010-08-05 |
Forsight Labs, Llc |
Posterior segment drug delivery
|
WO2010132459A2
(en)
|
2009-05-11 |
2010-11-18 |
Cleveland Clinic Foundation |
Biomarkers for assessment of age-related macular degeneration
|
US20110212433A1
(en)
|
2009-07-02 |
2011-09-01 |
Lanza Tech New Zealand Limited |
Alcohol production process
|
EP2451983B1
(en)
|
2009-07-10 |
2015-05-06 |
The Regents of the University of Michigan |
Methods for diagnosing macular degeneration
|
US20120190578A1
(en)
|
2009-08-06 |
2012-07-26 |
Washington University |
Plasma Complement Components as Expression Markers for Age-Related Macular Degeneration and Related Phenotypes
|
EA201200270A1
(en)
|
2009-08-12 |
2012-07-30 |
Пьюэр Байосайнс |
COMPOSITION AND METHODS OF APPLICATION OF ANHYDROUS DISINFECTING MEANS
|
US20110165648A1
(en)
|
2009-11-04 |
2011-07-07 |
Menno Van Lookeren Campagne |
Co-crystal structure of factor D and anti-factor D antibody
|
CA2778864C
(en)
*
|
2009-11-19 |
2017-06-27 |
Merck Serono S.A. |
Humanized antibodies against human il-22ra
|
EP2507381A4
(en)
|
2009-12-04 |
2016-07-20 |
Hoffmann La Roche |
Multispecific antibodies, antibody analogs, compositions, and methods
|
CN102108119A
(en)
|
2009-12-25 |
2011-06-29 |
天津键凯科技有限公司 |
Multi-arm polyethylene glycol derivative, combination thereof with medicine, and gel
|
BR112013005116A2
(en)
*
|
2010-09-03 |
2019-09-24 |
Stem Centrx Inc |
modulators and methods of use
|
CA2816805A1
(en)
|
2010-11-01 |
2012-05-10 |
Genentech, Inc. |
Predicting progression to advanced age-related macular degeneration using a polygenic score
|
AU2012239997A1
(en)
*
|
2011-04-07 |
2013-10-17 |
Amgen Inc. |
Novel EGFR binding proteins
|
US9738727B2
(en)
|
2011-10-14 |
2017-08-22 |
Genentech, Inc. |
Anti-HtrA1 antibodies and methods of use
|
JP6051998B2
(en)
|
2012-03-30 |
2016-12-27 |
日油株式会社 |
Multi-arm type polyethylene glycol derivative, its intermediate and production method
|
ES2687282T3
(en)
*
|
2013-03-18 |
2018-10-24 |
Biocerox Products B.V. |
ANTI-CD134 (OX40) humanized antibodies and their uses
|
EA201690213A1
(en)
|
2013-08-12 |
2016-07-29 |
Дженентек, Инк. |
COMPOSITIONS AND METHOD FOR TREATMENT OF CONNECTED STATES
|
MX2016002720A
(en)
*
|
2013-09-06 |
2016-06-08 |
Hoffmann La Roche |
Method for improving antibody stability.
|
AR099625A1
(en)
*
|
2014-03-21 |
2016-08-03 |
Lilly Co Eli |
IL-21 ANTIBODIES
|
MA39934A
(en)
|
2014-05-01 |
2017-03-08 |
Hoffmann La Roche |
Anti-factor d antibody variants and uses thereof
|
US10654932B2
(en)
|
2015-10-30 |
2020-05-19 |
Genentech, Inc. |
Anti-factor D antibody variant conjugates and uses thereof
|
AU2016344146A1
(en)
|
2015-10-30 |
2018-05-10 |
Genentech, Inc. |
Methods of measuring Factor D activity and potency of Factor D inhibitors
|
EP3368565A1
(en)
|
2015-10-30 |
2018-09-05 |
H. Hoffnabb-La Roche Ag |
Anti-factor d antibody formulations
|
TW201730211A
(en)
|
2015-10-30 |
2017-09-01 |
建南德克公司 |
Anti-Factor D antibodies and conjugates
|